Details

Autor(en) / Beteiligte

• Bonfiglioli, Karina Rossi
• da Mota, Licia Maria Henrique
• de Medeiros Ribeiro, Ana Cristina
• Kakehasi, Adriana Maria
• Laurindo, Ieda Maria Magalhães
• Giorgi, Rina Dalva Neubarth
• Duarte, Angela Luzia Branco Pinto
• Reis, Ana Paula Monteiro Gomides
• Ubirajara E Silva de Souza, Mariana Peixoto Guimarães
• Brenol, Claiton Viegas
• da Rocha Castelar Pinheiro, Geraldo
• de Albuquerque, Cleandro Pires
• de Moura Castro, Charlles Heldan
• Pinto, Gustavo Luiz Behrens
• Verztman, Jose Fernando
• Muniz, Luciana Feitosa
• Bertolo, Manoel Barros
• da Costa Pinto, Maria Raquel
• Louzada Júnior, Paulo
• Cruz, Vitor Alves
• Pereira, Ivanio Alves
• de Freitas, Max Vitor Carioca
• Cruz, Bóris Afonso
• Paiva, Eduardo
• Monticielo, Odirlei
• Provenza, José Roberto
• Xavier, Ricardo Machado

Titel

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Ist Teil von

• Advances in rheumatology (London, England), 2021-11, Vol.61 (1), p.70-70, Article 70

Ort / Verlag

England: Sociedade Brasileira de Reumatologia

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.